IL115642A0 - Her4 human receptor tyrosine kinase - Google Patents
Her4 human receptor tyrosine kinaseInfo
- Publication number
- IL115642A0 IL115642A0 IL11564295A IL11564295A IL115642A0 IL 115642 A0 IL115642 A0 IL 115642A0 IL 11564295 A IL11564295 A IL 11564295A IL 11564295 A IL11564295 A IL 11564295A IL 115642 A0 IL115642 A0 IL 115642A0
- Authority
- IL
- Israel
- Prior art keywords
- tyrosine kinase
- receptor tyrosine
- human receptor
- her4
- her4 human
- Prior art date
Links
- 102000027426 receptor tyrosine kinases Human genes 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32344294A | 1994-10-14 | 1994-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL115642A0 true IL115642A0 (en) | 1996-01-19 |
Family
ID=23259216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11564295A IL115642A0 (en) | 1994-10-14 | 1995-10-15 | Her4 human receptor tyrosine kinase |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0787187A1 (sv) |
JP (1) | JPH10507362A (sv) |
AU (1) | AU3963295A (sv) |
CA (1) | CA2202533A1 (sv) |
FI (1) | FI971532A (sv) |
IL (1) | IL115642A0 (sv) |
MX (1) | MX9702664A (sv) |
NO (1) | NO971686L (sv) |
WO (1) | WO1996012019A2 (sv) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9805398A (en) * | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
AU1518799A (en) * | 1997-10-31 | 1999-05-24 | Georgetown University Medical Center | Erbb-4 targeted ribozymes |
CA2515081A1 (en) | 2003-02-07 | 2004-08-19 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
WO2010056406A1 (en) | 2008-11-12 | 2010-05-20 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of erbb4 as a prognostic and therapeutic marker for melanoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
-
1995
- 1995-10-10 JP JP8513469A patent/JPH10507362A/ja active Pending
- 1995-10-10 MX MX9702664A patent/MX9702664A/es unknown
- 1995-10-10 CA CA002202533A patent/CA2202533A1/en not_active Abandoned
- 1995-10-10 WO PCT/US1995/013524 patent/WO1996012019A2/en not_active Application Discontinuation
- 1995-10-10 AU AU39632/95A patent/AU3963295A/en not_active Abandoned
- 1995-10-10 EP EP95937555A patent/EP0787187A1/en not_active Withdrawn
- 1995-10-15 IL IL11564295A patent/IL115642A0/xx unknown
-
1997
- 1997-04-11 NO NO971686A patent/NO971686L/no not_active Application Discontinuation
- 1997-04-11 FI FI971532A patent/FI971532A/sv not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2202533A1 (en) | 1996-04-25 |
AU3963295A (en) | 1996-05-06 |
JPH10507362A (ja) | 1998-07-21 |
NO971686D0 (no) | 1997-04-11 |
MX9702664A (es) | 1997-06-28 |
FI971532A0 (sv) | 1997-04-11 |
EP0787187A1 (en) | 1997-08-06 |
NO971686L (no) | 1997-06-16 |
WO1996012019A3 (en) | 1996-08-15 |
FI971532A (sv) | 1997-06-11 |
WO1996012019A2 (en) | 1996-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL107661A0 (en) | Her4 human receptor tyrosine kinase | |
EG24134A (en) | Quinazoline derivatives | |
ZA9610725B (en) | Tyrosine derivatives | |
HRP960147B1 (en) | Quinazoline derivatives | |
GB9508537D0 (en) | Quinazoline derivatives | |
HU9603525D0 (en) | Vironectin receptor antagonists | |
GB9508535D0 (en) | Quinazoline derivative | |
HU9700344D0 (en) | Substituted quinazoline derivatives | |
IL112673A0 (en) | Quinazoline derivatives | |
GB9607729D0 (en) | Quinazoline derivatives | |
IL124859A0 (en) | Tyrosine kinase receptors and ligands | |
IL115642A0 (en) | Her4 human receptor tyrosine kinase | |
ZA945372B (en) | Tyrosine kinase receptor | |
EP0792282A4 (en) | BOMBESIN AND ENDOTHELIN RECEPTOR OF HUMAN ORIGIN | |
EP0800531A4 (en) | NEW RECEPTOR TYROSINE KINASE | |
GB9513508D0 (en) | Quinazoline derivatives | |
GB9420389D0 (en) | Novel receptor tyrosine kinase | |
AU4750197A (en) | A human protein tyrosine kinase | |
GB9707776D0 (en) | Adjustable bed | |
IL110384A0 (en) | Tyrosine kinase receptor | |
GB9510574D0 (en) | Novel receptor tyrosine kinases | |
AU1120895A (en) | Novel receptor tyrosine kinase | |
ZA948394B (en) | Human endothelin-bombesin receptor | |
CA77706S (en) | Bedspring | |
GB9508536D0 (en) | Quinazoline derivative |